Melissa L. Johnson
梅丽莎·约翰逊
MD
Director, Lung Cancer Research Program肺癌研究项目主任
👥Biography 个人简介
Dr. Melissa Johnson is a prominent thoracic oncologist and clinical trialist at Sarah Cannon. She has been a lead investigator on IMpower133 and CheckMate trials evaluating nivolumab in SCLC, and has contributed substantially to expanding immunotherapy options in thoracic malignancies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Immunotherapy in SCLC
Key investigator in nivolumab (CheckMate) and atezolizumab (IMpower133) SCLC trials, helping define the role of immune checkpoint inhibitors in first-line and relapsed settings.
Representative Works 代表性著作
Nivolumab for recurrent small-cell lung cancer: results from the randomized, open-label phase III CheckMate 331 trial
Annals of Oncology (2021)
Phase III evaluation of nivolumab versus chemotherapy in relapsed SCLC, providing critical data on immunotherapy sequencing.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 梅丽莎·约翰逊 的研究动态
Follow Melissa L. Johnson's research updates
留下邮箱，当我们发布与 Melissa L. Johnson（Sarah Cannon Research Institute / Tennessee Oncology）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment